Payment overview · 2025
General Payments
$170,481.49
184 reported records · 6 companies
Healthcare provider profile · identity verified
Michael George Saribalas
Allopathic & Osteopathic Physicians|Family Medicine|Sleep Medicine · COLUMBUS, OH · NPI 1164454211
Verified facts
What the public records show
CMS Open Payments records show Michael George Saribalas received $170,481.49 in general payments during 2025 across 184 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 66.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Lybalvi, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Auvelity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $113,664.33 | 66.7% | 127 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17,265.22 | 10.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15,815.00 | 9.3% | 16 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15,404.45 | 9.0% | 23 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $8,181.51 | 4.8% | 8 | 2025 |
| Noctrix Health, Inc. | Unresolved — no canonical attribution shown | $150.98 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $128,302.00 | 46 |
| Travel and Lodging | $17,991.73 | 73 |
| Honoraria | $16,538.00 | 4 |
| Consulting Fee | $3,990.00 | 5 |
| Food and Beverage | $3,659.76 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $111,594.33 | 124 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17,265.22 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15,815.00 | 16 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15,404.45 | 23 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $8,181.51 | 8 | 2025 |
Source payment records
|
|||||
| NIDRA Normalized: nidra |
Device | Noctrix Health, Inc. | $150.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 90 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 173 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
173 | 31 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 329 | 76 |
| Trazodone Hcl | Trazodone Hcl | 273 | 75 |
| Quetiapine Fumarate | Quetiapine Fumarate | 191 | 31 |
| Bupropion Xl | Bupropion Hcl | 190 | 40 |
| Trintellix | Vortioxetine Hydrobromide | 179 | 33 |
| Clonazepam | Clonazepam | 176 | 48 |
| Lamotrigine | Lamotrigine | 174 | 37 |
| Vraylar | Cariprazine Hcl | 173 | 31 |
| Doxepin Hcl | Doxepin Hcl | 138 | 35 |
| Topiramate | Topiramate | 131 | 27 |
| Mirtazapine | Mirtazapine | 127 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 126 | 36 |
| Buspirone Hcl | Buspirone Hcl | 121 | 36 |
| Sertraline Hcl | Sertraline Hcl | 119 | 28 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 118 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 117 | 26 |
| Aripiprazole | Aripiprazole | 115 | 29 |
| Olanzapine | Olanzapine | 112 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 109 | 34 |
| Lorazepam | Lorazepam | 109 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 27 |
| Risperidone | Risperidone | 108 | 18 |
| Gabapentin | Gabapentin | 106 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | 25 |
| Vilazodone Hcl | Vilazodone Hcl | 104 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 25 |
| Diazepam | Diazepam | 99 | 29 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 90 | 17 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 79 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 19 |
| Ziprasidone Hcl | Ziprasidone Hcl | 73 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 71 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 70 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 17 |
| Temazepam | Temazepam | 62 | 20 |
| Alprazolam Er | Alprazolam | 61 | 13 |
| Rexulti | Brexpiprazole | 61 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 58 | 18 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 57 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 18 |
| Aristada | Aripiprazole Lauroxil | 56 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 48 | 12 |
| Clozapine | Clozapine | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Ramelteon | Ramelteon | 43 | 17 |
| Tiagabine Hcl | Tiagabine Hcl | 40 | 14 |
| Lithium Carbonate | Lithium Carbonate | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 36 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 33 | suppressed |
| Haloperidol | Haloperidol | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Fetzima | Levomilnacipran Hcl | 27 | suppressed |
| Modafinil | Modafinil | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 25 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 19 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 18 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 18 | suppressed |
| Quviviq | Daridorexant Hcl | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 15 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Protriptyline Hcl | Protriptyline Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Viibryd | Vilazodone Hcl | 12 | suppressed |
| Alprazolam Xr | Alprazolam | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170,481.49 · 184 records | E.R. Squibb & Sons, L.L.C. | Auvelity, COBENFY, FANAPT, LYBALVI, NIDRA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error